Shield Therapeutics plc announces that it has entered into an exclusive licence agreement for Accrufer® with KYE Pharmaceuticals Inc. in Canada. For further details click here.
Back to news5 Jan 2022
Shield Therapeutics plc announces that it has entered into an exclusive licence agreement for Accrufer® with KYE Pharmaceuticals Inc. in Canada. For further details click here.
Back to news